Document 2880
 DOCN  M94A2880
 TI    Vesnarinone; a preliminary therapeutic approach in HIV-1 infection.
 DT    9412
 AU    Maruyama Y; Kobayashi N; Maruyama I; Osame M; Third Department of
       Internal Medicine, School of Medicine,; Kagoshima University, Japan.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):203 (abstract no. PB0241). Unique
       Identifier : AIDSLINE ICA10/94369695
 AB    OBJECTIVE: To investigate the efficacy and safety of a new
       anti-retroviral agent, vesnarinone. METHODS: Studied were nine patients
       with HIV-1 infected hemophiliacs (30.3 +/- 5.6 years old, male, AIDS 5,
       ARC 3, AC 1). Eight patients received AZT and/or ddI in combination with
       vesnarinone. One patient received monotherapy with vesnarinone. All
       patients started to receive 60 mg daily oral vesnarinone. We evaluated
       peripheral blood cells, CD4 counts, HIV-1 proviral DNA and their
       clinical symptoms. RESULTS: There was no worsening of the HIV-1
       infection. CD 4 counts increased in 2 patients and HIV-1 proviral DNA
       decreased in 4 patients, 1-2 months after vesnarinone treatment. No
       patient had adverse drug reactions. DISCUSSION AND CONCLUSION:
       Vesnarinone inhibits production of HIV-1 and decreases the production of
       TNF-a and IL-6 in ex-vivo study (I. Maruyama, et al. BBRC 195, 1264,
       1993). Our preliminary data suggested that this may be a potentially
       effective anti-retroviral agent which is less toxic compared with AZT or
       ddI. To verify the efficacy of vesnarinone with anti-viral activity and
       cytokine levels, a nation-wide multicentric monotherapy trial has been
       started in Japan.
 DE    Antiviral Agents/ADVERSE EFFECTS/*PHARMACOLOGY  Didanosine/THERAPEUTIC
       USE  Drug Therapy, Combination  DNA, Viral/BLOOD
       Hemophilia/COMPLICATIONS  Human  HIV Infections/COMPLICATIONS/*DRUG
       THERAPY  *HIV-1/ISOLATION & PURIF  Leukocyte Count  Male
       Proviruses/ISOLATION & PURIF  Quinolines/ADVERSE EFFECTS/*PHARMACOLOGY
       Safety  Treatment Outcome  T4 Lymphocytes  Viremia/DRUG THERAPY
       Zidovudine/THERAPEUTIC USE  CLINICAL TRIAL  MEETING ABSTRACT
       MULTICENTER STUDY

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).